Biotech still runs on who owns the patent and who approves the drug. That was my takeaway from @alexkesin's session at DataDrivenPharma West last week. Alex wrote one of the most widely shared analyses of China's biotech rise this year, and it has become a reference point in the policy debate. He also co-hosts @approvedfm with [@MatthewPech], a podcast on how drugs get discovered, developed and sold. He walked a room of operators through where the value sits now. Four quick hits: - 1:3. Doing the work in China costs a half to a third of the US price. - Rent, don't sell. Beijing's new export controls block the sale of biotech platforms. Licensing, partnerships and contract research stay open. - 3x. China tripled its university patent conversion rate in two years, to 10.1%. - 8% to 32%. China's share of the global early-stage pipeline, from 2015 to 2024. The first hit explains the last five years. China got cheap and fast, and the West bought what it built. Most of those deals were fast-follows on targets Western labs discovered. The West owned the original IP and rented China's speed. The other three point to the next five. The export controls dropped the same morning as the session. Read them next to the new five-year plan, which makes biotech and biomanufacturing a national priority through 2030. The strategy looks clear to me. Generate IP faster than the US, keep ownership at home, and let the world license it. Pipeline share has quadrupled. Patents are moving out of universities and into companies. Nine out of ten still sit unused, so there's plenty of room to grow. Patents are still the currency. Regulators still set the exchange rate. The FDA turned away a Chinese PD-1 copycat because its trial ran only on Chinese patients. To get paid in the US, you still need FDA approval and a partner who can launch here. What changes is who holds the paper. When the West generated the IP, licensing meant Western companies owned the value and paid for speed. As more IP is generated and kept in China, the same deal structure sends more value the other way. The West ends up renting the molecule instead of owning it. This is a gold rush for intellectual property. The question is who can generate novel IP in a specific area, and do it first. Therapeutics is the beachhead. The US market pays enough for new drugs that the long road through the FDA still earns a return. In this gold rush, anyone can be a miner. The fastest ones will have the best maps. And maps only come from data. #ddpwest26